

01/10/00
1c377 U.S. PTO

1-11-00

A

Box 529

| | |
|--|------------------|
| Docket Number | 4-31157A/USN |
| FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10 | |
| EL402022937US | January 10, 2000 |
| Express Mail Label Number | Date of Deposit |

Address to: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET

Transmitted herewith for filing under 37 CFR §1.53(b) is the utility patent application of

Applicant (or identifier): Mary Ellen Digan, Philip Lake and Richard M. Wright

Title: ANTI-CD3 IMMUNOTOXINS AND THERAPEUTIC USES
THEREFOR

Enclosed are:

1. ☒ Specification (Including Claims and Abstract) - 115 pages
2. ☒ Drawings - 23 sheets
3. ☒ Unexecuted Declaration and Power of Attorney (original or copy)
4. ☐ Microfiche Computer Program (appendix)
5. ☐ Nucleotide and/or Amino Acid Sequence Submission
6. ☒ Computer Readable Copy
7. ☒ Paper Copy
8. ☒ Statement Verifying Identity of Above Copies
9. ☐ Preliminary Amendment
10. ☐ Assignment Papers (Cover Sheet & Document(s))
11. ☐ English Translation of
12. ☐ Information Disclosure Statement
13. ☐ Certified Copy of Priority Document(s)
14. ☒ Return Receipt Postcard
15. ☐ Other:

Filing fee calculation:

- ☐ Before calculating the filing fee, please enter the enclosed Preliminary Amendment.
- ☐ Before calculating the filing fee, please cancel claims

| | | | | | |
|---------------------------------------|--------------------|--------------|-----|--------------|------------------|
| Basic Filing Fee | | | | \$ 690 | |
| Multiple Dependent Claim Fee (\$ 260) | | | | \$ | |
| Foreign Language Surcharge (\$ 130) | | | | \$ | |
| | For | Number Filed | | Number Extra | Rate |
| Extra Claims | Total Claims | 29 | -20 | 9 | x \$ 18 = \$ 162 |
| | Independent Claims | 2 | -3 | 0 | x \$ 78 = \$ |
| TOTAL FILING FEE | | | | | \$ 852 |

1c678 U.S. PTO
09/480236
01/10/00

- ☒ Please charge Deposit Account No. 19-0134 in the name of Novartis Pharmaceuticals Corporation in the amount of \$852. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.


Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie
Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027

Please direct all telephone calls to the undersigned at the number given below, and all telefaxes to (908) 522-6955.

Respectfully submitted,

Date: January 10, 2000

 Jan. 10, 2000
Diane E. Furman
Attorney for Applicants
Reg. No. 31,104
Tel. No. (908) 522-6924